CRYOSITE LIMITED — Capital/Financing Update 2013

Dec 22, 2013

==> picture [161 x 48] intentionally omitted <==

23/12/2013 Company Announcements Office Australian Securities Exchange

Cryosite (ASX: CTE) Reports Half- year guidance update

Cryosite Limited (ASX: CTE). The Board of Cryosite would like to provide the market with a 2013-2014 profit guidance.

Following a review of the financial results to date, the Directors expect the half-year results to 31 December 2013 to be in line with expectations and similar to the results for the corresponding period last year.

However, as flagged in the Chairman’s address to the AGM held 6 November 2013, Cryosite is in the process of investing in a number of new development activities in both the biological services and warehousing and distribution segments that will have some negative, short- term financial affects.

We also expect that this will be compounded by the increased competitive landscape for the cord blood service due to increased marketing activity and sporadic discounting by our competitors.

Therefore, we expect that the full-year profit from continuing operations before income tax will be in the range of $800,000 to $1,000,000. This compares with the 2013 results of $1,180,998.

Gordon Milliken Managing Director 02 8862 2000

==> picture [452 x 60] intentionally omitted <==